December 9, 2005
The Food and Drug Administration has approved the hepatitis C treatment Ribasphere, co-manufactured by Par Pharmaceutical Cos. and Three Rivers Pharmaceuticals LLC, the companies said Monday. FDA approved Ribasphere, which uses the active ingredient ribavirin, in 200 mg, 400 mg and 600 mg tablets for use with interferon alfa-2a to treat hepatitis C.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Sex and the HIV Reservoir: New Research Points to the Powerful Effect of Estrogen|
|First U.S. Failure of Truvada as PrEP Is Reported at IDWeek|
|Post-AIDS 2018 Updates on HIV Cure Research|
|On-Demand PrEP Is Great. Now, What About Women?|
|High Rates of Anal HPV Infection in Gay Men Using PrEP in IPERGAY: The Role of Vaccination|